TD Asset Management
COAG

TD Asset Management’s Hemab Therapeutics COAG Stock Holding History

TD Asset Management’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
+33,098
New +$913K ﹤0.01% 1060

Other funds holding COAG

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TD Asset Management's COAG Position: Q2 2026 in Review

TD Asset Management opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 33,098 shares worth $1.22M. The stake represents ﹤0.01% of the portfolio and ranks #1060 among its holdings.

4 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

  • TD Asset Management held 33,098 shares of Hemab Therapeutics worth $1.22M as of Q2 2026.
  • Hemab Therapeutics was a new TD Asset Management position in Q2 2026.
  • Hemab Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1060 holding.
  • 4 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.